Apabetalone
Phase 3Small molecule
Apabetalone is one of 7 small molecule programs targeting End-Stage Renal Disease. It is currently in Phase 3.
2
Indications
6
Total Trials
2
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in End-Stage Renal Disease
#DrugCompanyPhaseTrials
1Prograf
VVeloxis Pharmaceuticals
Approved
Apabetalone
RResverlogix Corp
Phase 3
Wellbutrin
GSKPreclinical
Ribupatide
KKailera
Phase 1
Sevelamer Hydrochloride
SanofiPreclinical
Equine Anti-Thymocyte Globulin
NNational Cancer Institute (NCI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pulmonary Arterial Hypertension2 trials
End-Stage Renal Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Apabetalone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RResverlogix Corp